title: EGFR Promoter Methylation, EGFR Mutation, and HPV Infection in Chinese Cervical Squamous Cell Carcinoma.
abstract: Therapy strategy toward epidermal growth factor receptor (EGFR) inhibition in cervical cancer has been ongoing. EGFR promoter methylation status and EGFR tyrosine kinase inhibitor-sensitive mutations in cervical cancer may be significant for clinical outcome prediction using anti-EGFR treatment. In this study, EGFR tyrosine kinase inhibitor-sensitive mutations, EGFR exons 18, 19, and 21 mutations, were detected by sequencing in a total of 293 Chinese cervical squamous cell carcinoma tissue samples. EGFR promoter methylation status was detected by an EGFR asymmetric PCR and hybridization-fluorescence polarization assay and sequencing in 293 Chinese cervical squamous cell carcinoma tissue samples. High-risk human papillomavirus (HPV) genotypes in 293 Chinese cervical squamous cell carcinoma tissue samples were detected by an asymmetric GP5+/6+ PCR and hybridization-fluorescence polarization assay. No EGFR exons 18, 19, and 21 mutations were detected, EGFR promoter methylation status was identified in 98 samples, and HPV 16 infection was the first frequent HPV genotype. The methylated EGFR promoter was identified most frequently in cervical squamous cell carcinoma samples with HPV 16 infection (53.4%). Statistical significant difference of EGFR promoter methylation prevalence was found between HPV 16 and other HPV genotypes (P<0.01). This study suggested that there was no EGFR tyrosine kinase inhibitor-sensitive mutation in EGFR exons 18, 19, and 21 in Chinese cervical squamous cell carcinoma tissue samples. EGFR promoter methylation was common and it might be associated with HPV 16 infection in Chinese cervical squamous cell carcinoma. The results provided a novel understanding and an applicable pharmacogenomic tool for individualized management of cervical cancer patients.
authors: *Institute of Gene Diagnosis, State Key Laboratory of Cancer Biology, School of Pharmacology Departments of †Gynecology and Obstetrics §Oncology, Xijing Hospital, The Fourth Military Medical University ‡Department of Gynecology and Obstetrics, 2nd Affiliated Hospital, Medical School of Xian Jiaotong University, Xian, Shaanxi, China.
authors: Wei
authors: W
authors: Zhang
authors: Yinghao
authors: Y
authors: Jiang
authors: Qingmiao
authors: Q
authors: Yu
authors: Shaoying
authors: S
authors: Qiang
authors: Ping
authors: P
authors: Liang
authors: Yane
authors: Y
authors: Gao
authors: Xingye
authors: X
authors: Zhao
authors: Wenchao
authors: W
authors: Liu
authors: Ju
authors: J
authors: Zhang
mesh_terms: D000328:Adult; D044466:Asian People; D002294:Carcinoma, Squamous Cell / Q000208:ethnology / Q000235:genetics* / Q000473:pathology / Q000821:virology; D002584:Cervix Uteri / Q000378:metabolism / Q000473:pathology / Q000821:virology; D019175:DNA Methylation; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons; D005260:Female; D015870:Gene Expression; D052162:Human papillomavirus 16 / Q000472:pathogenicity / Q000502:physiology; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods; D009154:Mutation; D030361:Papillomavirus Infections / Q000208:ethnology / Q000235:genetics* / Q000473:pathology / Q000821:virology; D016133:Polymerase Chain Reaction / Q000379:methods; D011401:Promoter Regions, Genetic; D017422:Sequence Analysis, DNA; D002583:Uterine Cervical Neoplasms / Q000208:ethnology / Q000235:genetics* / Q000473:pathology / Q000821:virology
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors